Loading...
XETREVT
Market cap1.55bUSD
Dec 23, Last price  
8.41EUR
1D
0.12%
1Q
42.06%
Jan 2017
12.73%
Name

Evotec SE

Chart & Performance

D1W1MN
XETR:EVT chart
P/E
—
P/S
1.91
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-9.72%
Rev. gr., 5y
15.79%
Revenues
781m
+3.99%
1,936,41064,115,00067,354,00032,885,00039,613,00042,683,00055,262,00080,128,00087,265,00085,938,00089,496,000127,677,000164,507,000257,630,000375,405,000446,437,000500,924,000618,034,000751,448,000781,426,000
Net income
-84m
L-52.23%
0-33,583,000-32,468,000-11,156,000-78,287,000-45,497,0003,260,0006,749,0002,478,000-25,433,000-6,978,00016,516,00027,530,00024,257,00084,172,00038,156,0006,278,000215,510,000-175,655,000-83,913,000
CFO
36m
-82.06%
0-2,137,000-9,225,000-31,672,000-41,278,000-21,853,000899,00010,146,00011,957,0006,657,000-3,797,00015,651,00067,360,00010,828,000156,240,00042,216,00044,721,000122,237,000203,106,00036,439,000
Earnings
Jun 10, 2025

Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
URL
https://www.evotec.com/
IPO date
Oct 11, 1999
Employees
5,067
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
781,426
3.99%
751,448
21.59%
618,034
23.38%
Cost of revenue
833,504
810,215
644,136
Unusual Expense (Income)
NOPBT
(52,078)
(58,767)
(26,102)
NOPBT Margin
Operating Taxes
3,320
21,698
21,470
Tax Rate
NOPAT
(55,398)
(80,465)
(47,572)
Net income
(83,913)
-52.23%
(175,655)
-181.51%
215,510
3,332.78%
Dividends
Dividend yield
Proceeds from repurchase of equity
219
355
403,126
BB yield
Debt
Debt current
149,086
16,381
50,609
Long-term debt
665,714
667,116
612,745
Deferred revenue
206,136
34,476
Other long-term liabilities
237,460
17,404
18,488
Net debt
68,594
(196,818)
(482,153)
Cash flow
Cash from operating activities
36,439
203,106
122,237
CAPEX
(213,321)
(181,354)
(118,943)
Cash from investing activities
(13,291)
(415,823)
(243,855)
Cash from financing activities
71,963
(52,414)
398,430
FCF
(206,345)
(251,484)
(194,872)
Balance
Cash
604,112
729,983
858,498
Long term investments
142,094
150,332
287,009
Excess cash
707,135
842,743
1,114,605
Stockholders' equity
(329,747)
(252,826)
(52,451)
Invested Capital
2,266,728
2,161,237
1,985,421
ROIC
ROCE
EV
Common stock shares outstanding
176,917
176,674
167,128
Price
Market cap
EV
EBITDA
40,901
22,892
41,506
EV/EBITDA
Interest
11,739
13,150
9,254
Interest/NOPBT